US-based researchers have developed a transdermal vaccine for
Alzheimers disease which has been shown to clear brain-damaging
amyloid plaques in preclinical studies, offering hope to millions
of sufferers worldwide.
Patients suffering from Alzheimer's disease are one step closer to
receiving Novartis's Exelon as a transdermal patch instead of a
capsule following an international clinical study which showed that
the new delivery method...
A Phase I clinical trial, which is investigating the
pharmacological activities of a compound for the treatment of
Alzheimer's disease, has just been completed with results
indicating improved efficacy and pharmacokinetics over...
Scientists from the University of California have discovered three
molecules that show great potential in the development of new
Alzheimer's drugs. The new therapy targets a protein that
accumulates in Alzheimer's victims...